Gerresheimer Announces Pre-Fillable Syringe Product Line Expansion
Gerresheimer has announced it will be expanding its ClearJect product line of pre-fillable syringes with a new 2.25-mL cyclic olefin polymer (COP) staked in needle (SIN) syringe.
German-based Gerresheimer has announced it will be expanding its ClearJect product line of pre-fillable syringes with a new 2.25-mL cyclic olefin polymer (COP) staked in needle (SIN) syringe, which will be produced in Pfreimd, Germany along with the 1-mL version.
COP is a high-performance polymer, which means that the new pre-fillable syringe, the Gx RTF ClearJect 2.25-mL syringe, is suitable for use as primary packaging for biopharmaceutical products. Additionally, as the polymer is considered to be well resistant to breakages, the syringes are suitable for use with aggressive or toxic products.
The range of COP syringes from Gerresheimer are designed to ISO 11040-6 standard and have been registered. Furthermore, the syringes have been engineered to also be used in autoinjectors.
More information on the Gx RTF ClearJect range of pre-fillable syringes is available on the company’s website.
Source: Gerresheimer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
